Cancer, COVID-19, and Antiviral Immunity: The CAPTURE Study

Lewis Au; Laura Amanda Boos; Anthony Swerdlow; Fiona Byrne; Scott T C Shepherd; Annika Fendler; Samra Turajlic; CAPTURE investigators

doi:10.1016/j.cell.2020.09.005

Cancer, COVID-19, and Antiviral Immunity: The CAPTURE Study

Cell. 2020 Oct 1;183(1):4-10. doi: 10.1016/j.cell.2020.09.005. Epub 2020 Sep 3.

Authors

Lewis Au¹, Laura Amanda Boos², Anthony Swerdlow³, Fiona Byrne⁴, Scott T C Shepherd¹, Annika Fendler⁴, Samra Turajlic⁵; CAPTURE investigators

Affiliations

¹ Renal and Skin Units, The Royal Marsden NHS Foundation Trust, London, UK; Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK.
² Renal and Skin Units, The Royal Marsden NHS Foundation Trust, London, UK.
³ Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
⁴ Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK.
⁵ Renal and Skin Units, The Royal Marsden NHS Foundation Trust, London, UK; Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK. Electronic address: samra.turajlic@crick.ac.uk.

Abstract

The SARS-CoV-2 pandemic has posed a significant challenge for risk evaluation and mitigation among cancer patients. Susceptibility to and severity of COVID-19 in cancer patients has not been studied in a prospective and broadly applicable manner. CAPTURE is a pan-cancer, longitudinal immune profiling study designed to address this knowledge gap.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Antibodies, Viral / immunology
COVID-19
Coronavirus Infections / complications*
Coronavirus Infections / immunology
Humans
Longitudinal Studies
Monitoring, Immunologic / methods*
Neoplasms / complications*
Neoplasms / immunology
Neoplasms / virology
Pandemics
Pneumonia, Viral / complications*
Pneumonia, Viral / immunology

Substances

Antibodies, Viral

Abstract

Publication types

MeSH terms

Substances

Grants and funding